This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.
Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link above. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: PL 00010/0079.
Adalat 5
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.
If you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Package leaflet: Information for the user
Adalat® 5 mg
Soft capsules
Nifedipine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Adalat capsules are and what they are used for
2. What you need to know before you take Adalat capsules
3. How to take Adalat capsules
4. Possible side effects
5. How to store Adalat capsules
6. Contents of the pack and other information
1. What Adalat capsules are and what they are used for
Adalat capsules contain nifedipine, which belongs to a group of medicines called calcium antagonists.
Adalat capsules are used to treat high blood pressure, angina(chest pain)or a condition called Raynaud’s phenomenon which causes discolouration (often whitening) of the fingers and toes.
For high blood pressure: Adalat capsules work by relaxing and expanding the blood vessels. This makes the blood flow more easily and lowers blood pressure. Lower blood pressure reduces the strain on your heart.
For angina: Adalat capsules work by relaxing and expanding the arteries supplying the heart. This allows more blood and oxygen to reach the heart and decreases the strain on it. Your angina attacks will be less severe and less frequent if there is less strain on the heart.
Adalat capsules can increase the risk of serious heart problems in patients with high blood pressure or angina. Because of this, Adalat capsules are only used in these patients if no other treatments are appropriate.
For Raynaud’s phenomenon: Adalat capsules work by relaxing and expanding the blood vessels in the fingers and toes. This helps ensure a good blood supply.
2. What you need to know before you take Adalat capsules
Do not take Adalat capsules:
Warnings and precautions
Talk to your doctor before taking Adalat capsules
Tell your doctor:
Also tell your doctor:
Other medicines and Adalat capsules
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Some medicines may affect the way Adalat capsules work. Tell your doctor if you are taking:
Adalat capsules with food and drink
You can take Adalat capsules either with or without food.
Do not drink grapefruit juice or eat grapefruit while taking Adalat capsules.
Do not start taking Adalat capsules within 3 days of drinking grapefruit juice or eating grapefruit. Tell your doctor if you have had grapefruit or grapefruit juice in this time. Also, do not drink grapefruit juice or eat grapefruit whilst taking Adalat capsules. Grapefruit juice is known to increase the blood levels of the active ingredient, nifedipine. This effect can last for at least 3 days.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
You may be able to use Adalat capsules but only after special consideration and agreement by your doctor.
Do not take Adalat capsules if you are breast-feeding. If you need to take Adalat capsules while breast-feeding, tell your doctor before taking this medicine.
Driving and using machines
Adalat capsules may make you feel dizzy, faint, extremely tired or have visual disturbances. Do not drive or operate machinery if you are affected in this way.
This may be more likely when you first start treatment, if you change tablets, or if you have drunk alcohol.
Adalat capsules contains Yellow orange S (E110)
May cause allergic reactions.
3. How to take Adalat capsules
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Do not take them with grapefruit juice.
You can take Adalat capsules either with or without food.
Use in children and adolescents: Adalat capsules are not recommended for use in children and adolescents below 18 years of age, because there are only limited data on the safety and efficacy in this population.
If you take more Adalat capsules than you should
Taking too many capsules may cause your blood pressure to become too low and your heartbeats to speed up or slow down. It may also lead to an increase in your blood sugar level or an increase in the acidity of your blood, swelling in the lungs, low blood oxygen levels and disturbances in consciousness, possibly leading to unconsciousness.
If you forget to take Adalat capsules
Take your normal dose immediately and continue taking your capsules as prescribed, waiting 8 hours before taking your next dose.
Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
If you notice:
If you develop:
Less serious side effects
Apart from the side effects listed above, these are the other side effects of Adalat capsules, starting with the more common ones:
Common side effects
(These may affect up to 1 in 10 people)
Uncommon side effects
(These may affect up to 1 in 100 people)
Rare side effects
(These may affect up to 1 in 1,000 people)
Other side effects
(Frequency not known: frequency cannot be estimated from the available data)
All of these symptoms usually go away when treatment with Adalat capsules is stopped.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine. .
5. How to store Adalat capsules
Keep this medicine out of the sight and reach of children.
Store your medicine in its original container. Protect from strong light and only remove the capsule from the blister strip when you are about to take it.
Do not store above 30°C.
Do not use this medicine after the expiry date which is stated on both the outer carton and on each blister strip of capsules after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Adalat capsules contain
Adalat capsules contain the active ingredient, nifedipine.
Adalat capsules also contain glycerol, purified water, saccharin sodium, peppermint oil and macrogol 400.
The capsule shell contains gelatine, glycerol, titanium dioxide (E171) and yellow orange S (E110).
What Adalat capsules look like and contents of the pack
Each oval, soft gelatine capsule is filled with a viscous yellow liquid containing 5 mg of nifedipine.
Each pack contains 90 capsules.
Marketing Authorisation Holder and Manufacturer
Marketing authorisation holder:
Manufacturer:
or
This leaflet was last revised in May 2017.
Product licence number: PL 00010/0079
V021_0